Scholarlink

<p>The preventive value of compression sleeves during docetaxel remains unclear, despite concerns about docetaxel-induced edema increasing breast cancer-related lymphedema (BCRL) risk. This randomized controlled trial evaluated whether prophylactic sleeve use reduces BCRL incidence and characterized docetaxel-induced edema trajectory and quality of life (QoL) impact. Eighty-three women were randomized to an intervention group (IG, <i>n</i> = 41) wearing 15–21 mmHg medical-grade sleeves during and 3 months after docetaxel chemotherapy, or to a usual-care group (UG, <i>n</i> = 42). The primary outcome was 2-year cumulative BCRL incidence, and secondary outcomes included the extracellular water-to-total body water (ECW/TBW) ratio and QoL (FACT-Taxane). Over 2 years, 14 participants (16.9%) developed BCRL with no significant between-group difference (HR 0.91; 95% CI 0.31–2.66; <i>P</i> = 0.869). Preventive sleeves significantly reduced the ECW/TBW ratio and arm volume (<i>P</i> = 0.010 and <i>P</i> = 0.008, respectively), but these reductions did not translate into a lower BCRL incidence. Notably, docetaxel-induced edema resolved spontaneously by 3 months post-chemotherapy in all participants, regardless of group. IG reported significantly worse QoL at 3 and 6 months (Δ = –8.47 and –9.81). The dissociation between edema reduction and lymphatic outcomes suggests that transient docetaxel-induced edema is unlikely to be a primary driver of chronic lymphedema, although a preventive benefit cannot be firmly excluded given the wide confidence interval. These findings do not support routine prophylactic sleeve use and highlight the need for targeted prevention in anatomically high-risk patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preventive effect of compression on breast cancer–related lymphedema after docetaxel chemotherapy: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Seung Mi Yeo,
  • Ji Young Lim,
  • Ji-Yeon Kim,
  • Young-Hyuck Im,
  • Ji Hye Hwang

摘要

The preventive value of compression sleeves during docetaxel remains unclear, despite concerns about docetaxel-induced edema increasing breast cancer-related lymphedema (BCRL) risk. This randomized controlled trial evaluated whether prophylactic sleeve use reduces BCRL incidence and characterized docetaxel-induced edema trajectory and quality of life (QoL) impact. Eighty-three women were randomized to an intervention group (IG, n = 41) wearing 15–21 mmHg medical-grade sleeves during and 3 months after docetaxel chemotherapy, or to a usual-care group (UG, n = 42). The primary outcome was 2-year cumulative BCRL incidence, and secondary outcomes included the extracellular water-to-total body water (ECW/TBW) ratio and QoL (FACT-Taxane). Over 2 years, 14 participants (16.9%) developed BCRL with no significant between-group difference (HR 0.91; 95% CI 0.31–2.66; P = 0.869). Preventive sleeves significantly reduced the ECW/TBW ratio and arm volume (P = 0.010 and P = 0.008, respectively), but these reductions did not translate into a lower BCRL incidence. Notably, docetaxel-induced edema resolved spontaneously by 3 months post-chemotherapy in all participants, regardless of group. IG reported significantly worse QoL at 3 and 6 months (Δ = –8.47 and –9.81). The dissociation between edema reduction and lymphatic outcomes suggests that transient docetaxel-induced edema is unlikely to be a primary driver of chronic lymphedema, although a preventive benefit cannot be firmly excluded given the wide confidence interval. These findings do not support routine prophylactic sleeve use and highlight the need for targeted prevention in anatomically high-risk patients.